Table 1.
Baseline clinical characteristics
| Characteristics | DWI-Guided DP-IMRT Number of patients (%) | Conventional MRI-based IMRT Number of patients (%) | P value |
|---|---|---|---|
| Total | 126 | 134 | |
| Age, y | 0.412 | ||
| Median | 57 | 56 | |
| Range | 31–75 | 31–75 | |
| Sex | 0.166 | ||
| Male | 115 (91.3) | 130 (97) | |
| Female | 11 (8.7) | 4 (3) | |
| Karnofsky Scale | 0.502 | ||
| 90–100 | 123 (97.6) | 128 (95.5) | |
| 70–80 | 3 (2.4) | 6 (4.5) | |
| Disease Primary Site | 0.086 | ||
| Oral Cavity | 18 (14.3) | 16 (11.9) | |
| Oropharynx | 48 (38.1) | 37 (27.6) | |
| Larynx | 3 (2.4) | 10 (7.5) | |
| Hypopharynx | 57 (45.2) | 71 (53.0) | |
| Disease State | 0.832 | ||
| III | 21 (16.7) | 20 (14.9) | |
| IV | 105 (83.3) | 114 (85.1) | |
| T Stage | 0.652 | ||
| T1 | 10 (7.9) | 9 (6.7) | |
| T2 | 37 (29.4) | 48 (35.9) | |
| T3 | 24 (19.0) | 20 (14.9) | |
| T4 | 55 (43.7) | 57 (42.5) | |
| N Stage | 0.918 | ||
| N0 | 6 (4.8) | 8 (5.9) | |
| N1 | 25 (19.8) | 23 (17.2) | |
| N2 | 80 (63.5) | 88 (65.7) | |
| N3 | 15 (11.9) | 15 (11.2) | |
| p16 | 0.137 | ||
| Positive | 13 (10.3) | 8 (6.0) | |
| Negative | 113 (89.7) | 126 (94.0) | |
| Immunotherapy | 35 (27.8) | 24 (14.3) |